Overexpressed KDM5B is associated with the progression of glioma and promotes glioma cell growth via downregulating p21

Biochemical and Biophysical Research Communications

Volumn 454, Issue 1, 2014, Pages 221-227

  Dai, Bin ^a   Hu, Zhiqiang ^a   Huang, Hui ^a   Zhu, Guangtong ^a   Xiao, Zhiyong ^a   Wan, Weiqing ^b   Zhang, Peng ^b   Jia, Wang ^b   Zhang, Liwei ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Glioma; KDM5B; Proliferation

Indexed keywords

PROTEIN P21; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE DEMETHYLASE; KDM5B PROTEIN, HUMAN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; TUMOR MARKER;

ARTICLE; BRAIN TISSUE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; EVIDENCE BASED PRACTICE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYSINE K SPECIFIC DEMETHYLASE 5B ONCOGENE; MAJOR CLINICAL STUDY; ONCOGENE; OVERALL SURVIVAL; SURVIVAL TIME; TUMOR GROWTH; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; BRAIN TUMOR; CASE CONTROL STUDY; DISEASE COURSE; DRUG SCREENING; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HETEROGRAFTS; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MICE; MICE, NUDE; NUCLEAR PROTEINS; ONCOGENES; REPRESSOR PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY; UP-REGULATION;

EID: 84910610773     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.10.078     Document Type: Article

References (33)

1. Z. Zhou, Z. Ji, Y. Wang, J. Li, H. Cao, H.H. Zhu, W.Q. Gao, TRIM59 is upregulated in gastric tumors, promoting ubiquitination and degradation of P53, Gastroenterology (2014).
2. X. Liu, H. Yu, H. Cai, Y. Wang, Expression of CD24, p21, p53, and c-myc in alpha-fetoprotein-producing gastric cancer: correlation with clinicopathologic characteristics and survival, J. Surg. Oncol. 109 (2014) 859-864.
3. W. Zhou, X.Q. Fu, L.L. Zhang, J. Zhang, X. Huang, X.H. Lu, L. Shen, B.N. Liu, J. Liu, H.S. Luo, J.P. Yu, H.G. Yu, The AKT1/NF-kappaB/Notch1/PTEN axis has an important role in chemoresistance of gastric cancer cells, Cell Death Dis. 4 (2013) e847.
4. M. El-Zaatari, J.Y. Kao, A. Tessier, L. Bai, M.M. Hayes, C. Fontaine, K.A. Eaton, J.L. Merchant, Gli1 deletion prevents Helicobacter-induced gastric metaplasia and expansion of myeloid cell subsets, PLoS ONE 8 (2013) e58935.
5. S.S. Kim, N.J. Yoo, E.G. Jeong, M.S. Kim, S.H. Lee, Expression of NEDD4-1, a PTEN regulator, in gastric and colorectal carcinomas, APMIS 116 (2008) 779-784.
6. Q. Wang, Y. Wang, Y. Zhang, Y. Zhang, W. Xiao, The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease, Respir. Res. 14 (2013) 67.
7. P. Li, X. Chen, L. Su, C. Li, Q. Zhi, B. Yu, H. Sheng, J. Wang, R. Feng, Q. Cai, J. Li, Y. Yu, M. Yan, B. Liu, Z. Zhu, Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP, PLoS ONE 8 (2013) e66782.
8. Z. Ali, Y. Deng, Y. Tang, S. Zheng, N. Ma, N. He, Epigenetic deregulations in gastric cancer, J. Nanosci. Nanotechnol. 13 (2013) 40-51.
9. L.L. Thompson, B.J. Guppy, L. Sawchuk, J.R. Davie, K.J. McManus, Regulation of chromatin structure via histone post-translational modification and the link to carcinogenesis, Cancer Metastasis Rev. 32 (2013) 363-376.
10. A.J. Bannister, T. Kouzarides, Regulation of chromatin by histone modifications, Cell Res. 21 (2011) 381-395.
11. M. Litt, Y. Qiu, S. Huang, Histone arginine methylations: their roles in chromatin dynamics and transcriptional regulation, Biosci. Rep. 29 (2009) 131-141.
12. H. Suzuki, R. Maruyama, E. Yamamoto, M. Kai, Epigenetic alteration and microRNA dysregulation in cancer, Front. Genet. 4 (2013) 258.
13. X. Li, Y. Su, J. Pan, Z. Zhou, B. Song, E. Xiong, Z. Chen, Connexin 26 is down-regulated by KDM5B in the progression of bladder cancer, Int. J. Mol. Sci. 14 (2013) 7866-7879.
14. Y. Sun, Y. Wang, C. Fan, P. Gao, X. Wang, G. Wei, J. Wei, Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation, Mol. Cancer 13 (2014) 137.
15. K. Ohta, N. Haraguchi, Y. Kano, Y. Kagawa, M. Konno, S. Nishikawa, A. Hamabe, S. Hasegawa, H. Ogawa, T. Fukusumi, M. Uemura, J. Nishimura, T. Hata, I. Takemasa, T. Mizushima, Y. Noguchi, M. Ozaki, T. Kudo, D. Sakai, T. Satoh, M. Fukami, M. Ishii, H. Yamamoto, Y. Doki, M. Mori, H. Ishii, Depletion of JARID1B induces cellular senescence in human colorectal cancer, Int. J. Oncol. 42 (2013) 1212-1218.
16. P.P. Wong, F. Miranda, K.V. Chan, C. Berlato, H.C. Hurst, A.G. Scibetta, Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A), Mol. Cell. Biol. 32 (2012) 1633-1644.
17. Y. Wang, M. Wen, Y. Kwon, Y. Xu, Y. Liu, P. Zhang, X. He, Q. Wang, Y. Huang, K.Y. Jen, M.A. LaBarge, L. You, S.C. Kogan, J.W. Gray, J.H. Mao, G. Wei, CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression, Cancer Res. 74 (2014) 520-531.
18. O. Tapia, I. Riquelme, P. Leal, A. Sandoval, S. Aedo, H. Weber, P. Letelier, E. Bellolio, M. Villaseca, P. Garcia, J.C. Roa, The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance, Virchows Arch. 465 (2014) 25-33.
19. Y. Wang, T. Jiang, Understanding high grade glioma: molecular mechanism, therapy and comprehensive management, Cancer Lett. 331 (2013) 139-146.
20. M.L. Goodenberger, R.B. Jenkins, Genetics of adult glioma, Cancer Genet. 205 (2012) 613-621.
21. J.V. Joseph, V. Balasubramaniyan, A. Walenkamp, F.A. Kruyt, TGF-beta as a therapeutic target in high grade gliomas - promises and challenges, Biochem. Pharmacol. 85 (2013) 478-485.
22. M. Lindgren, M. Johansson, J. Sandstrom, Y. Jonsson, A.T. Bergenheim, R. Henriksson, VEGF and tPA co-expressed in malignant glioma, Acta Oncol. 36 (1997) 615-618.
23. T. Abe, T. Tamiya, Y. Ono, A.H. Salker, K. Akiyama, T. Ohmoto, Accumulation of cell cycle regulatory proteins, p21 and p27, induced after hyperthermia in human glioma cells, Int. J. Hyperthermia 17 (2001) 499-507.
24. B. Wagenknecht, M. Hermisson, K. Eitel, M. Weller, Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells, Cell. Physiol. Biochem. 9 (1999) 117-125.
25. M.J. Pykett, E. Azzam, W. Dahlberg, J.B. Little, Differential p53, p21, mdm2 and Rb regulation in glioma cell lines that overexpress wild-type p53, Int. J. Oncol. 13 (1998) 213-216.
26. T. Komata, T. Kanzawa, H. Takeuchi, I.M. Germano, M. Schreiber, Y. Kondo, S. Kondo, Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells, Br. J. Cancer 88 (2003) 1277-1280.
27. K. Anton, J.M. Baehring, T. Mayer, Glioblastoma multiforme: overview of current treatment and future perspectives, Hematol. Oncol. Clin. North Am. 26 (2012) 825-853.
28. Y. Xu, Y. Wang, G. Ma, Q. Wang, G. Wei, CUL4A is overexpressed in human pituitary adenomas and regulates pituitary tumor cell proliferation, J. Neurooncol. 116 (2014) 625-632.
29. S. Venneti, M.M. Felicella, T. Coyne, J.J. Phillips, D. Gorovets, J.T. Huse, J. Kofler, C. Lu, T. Tihan, L.M. Sullivan, M. Santi, A.R. Judkins, A. Perry, C.B. Thompson, Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas, J. Neuropathol. Exp. Neurol. 72 (2013) 298-306.
30. K. Xu, Z.J. Wu, A.C. Groner, H.H. He, C. Cai, R.T. Lis, X. Wu, E.C. Stack, M. Loda, T. Liu, H. Xu, L. Cato, J.E. Thornton, R.I. Gregory, C. Morrissey, R.L. Vessella, R. Montironi, C. Magi-Galluzzi, P.W. Kantoff, S.P. Balk, X.S. Liu, M. Brown, EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent, Science 338 (2012) 1465-1469.
31. Z.S. Walters, B. Villarejo-Balcells, D. Olmos, T.W. Buist, E. Missiaglia, R. Allen, B. Al-Lazikani, M.D. Garrett, J. Blagg, J. Shipley, JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells, Oncogene 33 (2014) 1148-1157.
32. S. Hayami, M. Yoshimatsu, A. Veerakumarasivam, M. Unoki, Y. Iwai, T. Tsunoda, H.I. Field, J.D. Kelly, D.E. Neal, H. Yamaue, B.A. Ponder, Y. Nakamura, R. Hamamoto, Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway, Mol. Cancer 9 (2010) 59.
33. Y. Wang, G. Ma, Q. Wang, M. Wen, Y. Xu, X. He, P. Zhang, Y. Wang, T. Yang, P. Zhan, G. Wei, Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells, Molecules 19 (2013) 159-176.